

Ricardo Machado Xavier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/751371/publications.pdf>

Version: 2024-02-01

213
papers

5,790
citations

101543

36
h-index

98798

67
g-index

227
all docs

227
docs citations

227
times ranked

7728
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force. <i>Advances in Rheumatology</i> , 2022, 62, 3.	1.7	6
2	<i>MBL2</i> gene polymorphisms and its relation to infection in Brazilian systemic lupus erythematosus patients: A 10-years follow-up study. <i>Lupus</i> , 2022, 31, 279-286.	1.6	0
3	A Review of Metabolomic Profiling in Rheumatoid Arthritis: Bringing New Insights in Disease Pathogenesis, Treatment and Comorbidities. <i>Metabolites</i> , 2022, 12, 394.	2.9	8
4	The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	9
5	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
6	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021, 31, 534-542.	1.8	6
7	Efficacy and Safety of Tocilizumab for Polyarticular Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 530-541.	5.6	16
8	High Levels of Polypharmacy in Rheumatoid Arthritis – A Challenge Not Covered by Current Management Recommendations: Data From a Large Real-Life Study. <i>Journal of Pharmacy Practice</i> , 2021, 34, 365-371.	1.0	15
9	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. <i>Lupus</i> , 2021, 30, 630-640.	1.6	2
10	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021, 60, 4495-4507.	1.9	15
11	Practical screening tools for sarcopenia in patients with systemic sclerosis. <i>PLoS ONE</i> , 2021, 16, e0245683.	2.5	18
12	Effects of Participating in a Research Project During the COVID-19 Pandemic on Medical Students' Educational Routines and Mental Health: Protocol for a Web-Based Survey Study. <i>JMIR Research Protocols</i> , 2021, 10, e24617.	1.0	1
13	Survival of immunobiological drugs in psoriasis: preliminary data from a Tertiary Hospital experience in Southern Brazil. <i>Anais Brasileiros De Dermatologia</i> , 2021, 96, 376-379.	1.1	2
14	Nutritional aspects and cardiovascular risk in systemic lupus erythematosus. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 656-660.	0.7	4
15	CIITA gene polymorphism (rs3087456) in systemic lupus erythematosus and rheumatoid arthritis: A population-based cohort study. <i>International Journal of Immunogenetics</i> , 2021, 48, 429-434.	1.8	0
16	Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 303-321.	2.4	2
17	The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. <i>Lupus</i> , 2021, 30, 1684-1695.	1.6	7
18	Metabolomic Biomarker Candidates for Skeletal Muscle Loss in the Collagen-Induced Arthritis (CIA) Model. <i>Journal of Personalized Medicine</i> , 2021, 11, 837.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis. <i>Advances in Rheumatology</i> , 2021, 61, 56.	1.7	1
20	High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. <i>RMD Open</i> , 2021, 7, e001461.	3.8	49
21	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. <i>Advances in Rheumatology</i> , 2021, 61, 60.	1.7	5
22	Morphological Parameters in Quadriceps Muscle Were Associated with Clinical Features and Muscle Strength of Women with Rheumatoid Arthritis: A Cross-Sectional Study. <i>Diagnostics</i> , 2021, 11, 2014.	2.6	3
23	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
24	The effects of resistance training with blood flow restriction on muscle strength, muscle hypertrophy and functionality in patients with osteoarthritis and rheumatoid arthritis: A systematic review with meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0259574.	2.5	11
25	Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis. <i>Advances in Rheumatology</i> , 2021, 61, 70.	1.7	5
26	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
27	Height and sexual maturation in girls with juvenile idiopathic arthritis. <i>Jornal De Pediatria</i> , 2020, 96, 100-107.	2.0	7
28	Evaluation of the association between KIR polymorphisms and systemic sclerosis: a meta-analysis. <i>Advances in Rheumatology</i> , 2020, 60, 8.	1.7	2
29	T-cell specific upregulation of Sema4A as risk factor for autoimmunity in systemic lupus erythematosus and rheumatoid arthritis. <i>Autoimmunity</i> , 2020, 53, 65-70.	2.6	4
30	Vitamin D and Cytokine Profiles in Patients With Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 289-294.	0.9	11
31	Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2020, 26, S180-S186.	0.9	4
32	Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2020, 383, 1511-1521.	27.0	151
33	Quadriceps muscle properties in rheumatoid arthritis: insights about muscle morphology, activation and functional capacity. <i>Advances in Rheumatology</i> , 2020, 60, 28.	1.7	6
34	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. <i>Advances in Rheumatology</i> , 2020, 60, 32.	1.7	53
35	Discordance between the patient's and physician's global assessment in rheumatoid arthritis: Data from the REAL study in Brazil. <i>PLoS ONE</i> , 2020, 15, e0230317.	2.5	16
36	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. <i>Lupus</i> , 2020, 29, 1140-1145.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1607-1620.	5.6	126
38	Height and sexual maturation in girls with juvenile idiopathic arthritis. <i>Jornal De Pediatria (Versão Em Português)</i> / <i>Overlock 10 T</i>	0.2	0
39	Cachexia in patients with rheumatoid arthritis: a cohort study. <i>Clinical Rheumatology</i> , 2020, 39, 3603-3613.	2.2	16
40	SAT0151... EFFICACY AND SAFETY OF UPADACITINIB VERSUS ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-CHOICE): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1015-1016.	0.9	7
41	Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic Diseases: Protocol for a Multicentric Observational Cohort Study. <i>JMIR Research Protocols</i> , 2020, 9, e23532.	1.0	4
42	OPO269-HPR... ASSOCIATION OF SARC-F PERFORMANCE WITH COMORBIDITIES, PHYSICAL DISABILITY AND LOWER ALBUMIN LEVELS IN SYSTEMIC SCLEROSIS PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 168.2-168.	0.9	0
43	A Brazilian Cohort of Patients With Immuno-Mediated Chronic Inflammatory Diseases Infected by SARS-CoV-2 (ReumaCoV-Brasil Registry): Protocol for a Prospective, Observational Study. <i>JMIR Research Protocols</i> , 2020, 9, e24357.	1.0	13
44	Burden of rheumatoid arthritis on patients' work productivity and quality of life. <i>Advances in Rheumatology</i> , 2019, 59, 47.	1.7	43
45	Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI. <i>Advances in Rheumatology</i> , 2019, 59, 23.	1.7	21
46	Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort. <i>PLoS ONE</i> , 2019, 14, e0213219.	2.5	6
47	PANLAR consensus statement on biosimilars. <i>Clinical Rheumatology</i> , 2019, 38, 1485-1496.	2.2	9
48	OPO271... HPR ASSESSMENT OF MUSCLE MASS RELATIVE TO FAT MASS AND ITS ASSOCIATION WITH DISEASE ACTIVITY STATUS AND PHYSICAL FUNCTIONING IN RHEUMATOID ARTHRITIS. , 2019, , .		0
49	THU0197... MONOTHERAPY WITH UPADACITINIB IN MTX-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-EARLY STUDY. , 2019, , .		1
50	AB0089... IN VITRO EFFECT OF FASCIOLA HEPATICA EXTRACT ON SYNOVIAL FIBROBLAST OF RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		0
51	AB1331... URINE METABOLIC PROFILE IN RHEUMATOID ARTHRITIS DEVELOPMENT. , 2019, , .		0
52	AB0135... LEVELS OF MYOKINES AND RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
53	AB0219... BIOMARKER EXPRESSION IN MONOCYTE SUBPOPULATIONS IN SSC PATIENTS. , 2019, , .		0
54	<p>Clinical Improvements as Predictors of Improvements in Patient-Reported Outcomes: Post Hoc Analysis of a Randomized, Open-Label Study of Etanercept in Latin American Patients with Rheumatoid Arthritis</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 275-281.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1056-1064.	1.9	8
56	Treating psoriatic arthritis to target: discordance between physicians and patients' assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort. <i>Clinical Rheumatology</i> , 2019, 38, 961-968.	2.2	4
57	Collagen-induced arthritis as an animal model of rheumatoid cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 603-612.	7.3	51
58	Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 177-182.	0.9	8
59	Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. <i>Rheumatology</i> , 2018, 57, 499-507.	1.9	32
60	Capillary loss on nailfold capillary microscopy is associated with mortality in systemic sclerosis. <i>Clinical Rheumatology</i> , 2018, 37, 475-481.	2.2	11
61	Neuromuscular fatigue is weakly associated with perception of fatigue and function in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 415-423.	3.0	8
62	The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. <i>Advances in Rheumatology</i> , 2018, 58, 33.	1.7	5
63	THU0080...Serum irisin and myostatin levels in patients with rheumatoid arthritis. , 2018, , .		2
64	Nasal Administration of Cationic Nanoemulsions as Nucleic Acids Delivery Systems Aiming at Mucopolysaccharidosis Type I Gene Therapy. <i>Pharmaceutical Research</i> , 2018, 35, 221.	3.5	18
65	Intra-articular nonviral gene therapy in mucopolysaccharidosis I mice. <i>International Journal of Pharmaceutics</i> , 2018, 548, 151-158.	5.2	10
66	2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. <i>Advances in Rheumatology</i> , 2018, 58, 2.	1.7	25
67	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del Tj ETQq1 1 0.784314 rgBT/Overlo Diseases. 2018, 77, 1549-1557.	0.9	96
68	Human immunodeficiency virus in a cohort of systemic lupus erythematosus patients. <i>Advances in Rheumatology</i> , 2018, 58, 12.	1.7	7
69	Fears and beliefs of people living with rheumatoid arthritis: a systematic literature review. <i>Advances in Rheumatology</i> , 2018, 58, 1.	1.7	29
70	Muscle wasting in osteoarthritis model induced by anterior cruciate ligament transection. <i>PLoS ONE</i> , 2018, 13, e0196682.	2.5	27
71	Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 816-825.	7.3	83
72	THU0318...Treating psoriatic arthritis to target: comorbidities, non-adherence and factors related to the health system prevent escalation of therapy in real life. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
73	<i>CCR5^{Δ32}</i> and the genetic susceptibility to rheumatoid arthritis in admixed populations: a multicentre study. <i>Rheumatology</i> , 2017, 56, kew398.	1.9	6
74	Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 385-391.	0.7	3
75	Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 493-500.	2.4	27
76	Disease modifying anti-rheumatic activity of the alkaloid montanine on experimental arthritis and fibroblast-like synoviocytes. <i>European Journal of Pharmacology</i> , 2017, 799, 180-187.	3.5	17
77	Evaluation of polymorphic variants in apoptotic genes and their role in susceptibility and clinical progression to systemic lupus erythematosus. <i>Lupus</i> , 2017, 26, 746-755.	1.6	14
78	Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 228-234.	3.4	41
79	Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 403-411.	0.7	15
80	Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study. <i>Rheumatology International</i> , 2017, 37, 993-997.	3.0	14
81	As decisões de tratamento com DMARD na artrite reumatoide parecem ser influenciadas pela fibromialgia. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 403-411.	0.8	12
82	FR10066...Gastrin-releasing peptide and its receptor increase arthritis fibroblast-like synoviocyte invasiveness over the pi3k/akt pathway. , 2017, , .		0
83	Gastrin-releasing peptide and its receptor increase arthritis fibroblast-like synoviocytes invasiveness through activating the PI3K/AKT pathway. <i>Peptides</i> , 2017, 95, 57-61.	2.4	11
84	SAT0199...Subcutaneous tocilizumab monotherapy or combined with a csdmard in patients with rheumatoid arthritis: tozura, a pooled analysis of phase iv studies in 22 countries. , 2017, , .		1
85	Deletion of eIF2 ² lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth. <i>Cancer Biology and Therapy</i> , 2017, 18, 560-570.	3.4	5
86	Correlação entre expressão celular de proteínas reguladoras do complemento com a depleção e repopulação de linfócitos B no sangue periférico de pacientes com artrite reumatoide tratada com rituximabe. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 385-391.	0.8	3
87	FR10768-HPR...Muscle wasting in osteoarthritis model induced by anterior cruciate ligament transection. , 2017, , .		1
88	AB0960...Growth and sexual maturation in girls with juvenile idiopathic arthritis. , 2017, , .		0
89	THU0520...Pelvic ultrasound in the assessment of sexual maturity in girls with juvenile idiopathic arthritis. , 2017, , .		0
90	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. <i>PLoS ONE</i> , 2017, 12, e0175207.	2.5	92

#	ARTICLE	IF	CITATIONS
91	Matrix metalloproteinase gene polymorphisms and susceptibility to systemic sclerosis. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.2	13
92	Ficolin Gene Polymorphisms in Systemic Lupus Erythematosus and Rheumatoid Arthritis. <i>Annals of Human Genetics</i> , 2016, 80, 1-6.	0.8	20
93	Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia – A controlled cross-sectional study. <i>Cytokine</i> , 2016, 84, 25-28.	3.2	50
94	Vitamin D receptor polymorphisms and expression profile in rheumatoid arthritis brazilian patients. <i>Molecular Biology Reports</i> , 2016, 43, 41-51.	2.3	14
95	Assessment of anti-MÃ¼llerian hormone levels in premenopausal patients with systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 227-232.	1.6	26
96	Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region. <i>Open Rheumatology Journal</i> , 2016, 10, 13-25.	0.2	3
97	Preliminary guidelines of the Brazilian Society of Rheumatology for evaluation and treatment of tuberculosis latent infection in patients with rheumatoid arthritis, in face of unavailability of the tuberculin skin test. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 390-393.	0.7	1
98	Effect of pegylated phosphatidylserine-containing liposomes in experimental chronic arthritis. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 24.	2.4	9
99	The Spectrum and Clinical Significance of Autoantibodies in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2015, 6, 320.	4.8	3
100	Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 512-521.	0.7	0
101	Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study. <i>Clinical Rheumatology</i> , 2015, 34, 1781-1785.	2.2	10
102	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1110-1117.	0.9	251
103	Anti-MÃ¼llerian hormone levels as a predictor of ovarian reserve in systemic lupus erythematosus patients: a review. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 363-367.	0.7	0
104	Clinical and radiographic outcomes at 2â€¦years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 35-43.	0.9	94
105	Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso 2012da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide. <i>Revista Brasileira De Reumatologia</i> , 2015, 55, 512-521.	0.8	10
106	Electroconvulsive therapy as a treatment for refractory neuropsychiatric lupus with catatonia: three case studies and literature review. <i>Lupus</i> , 2015, 24, 1327-1331.	1.6	13
107	Catchâ€Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial. <i>Arthritis and Rheumatology</i> , 2015, 67, 840-848.	5.6	63
108	Is Ultrasound a Better Target than Clinical Disease Activity Scores in Rheumatoid Arthritis with Fibromyalgia? A Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0118620.	2.5	29

#	ARTICLE	IF	CITATIONS
109	The Paradox of High Availability and Low Recognition of Soluble HLA-G by LILRB1 Receptor in Rheumatoid Arthritis Patients. <i>PLoS ONE</i> , 2015, 10, e0123838.	2.5	19
110	<sc>HLA</sc> +3142 polymorphism as a susceptibility marker in two rheumatoid arthritis populations in Brazil. <i>Tissue Antigens</i> , 2014, 83, 260-266.	1.0	21
111	Open-Label Observation of Addition of Etanercept Versus a Conventional Disease-Modifying Antirheumatic Drug in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy in the Latin American Region. <i>Journal of Clinical Rheumatology</i> , 2014, 20, 25-33.	0.9	36
112	SIRT1 promoter polymorphisms as clinical modifiers on systemic lupus erythematosus. <i>Molecular Biology Reports</i> , 2014, 41, 4233-4239.	2.3	34
113	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014, 66, S5-S6.	5.6	4
114	Assessment of nailfold capillaroscopy in systemic sclerosis by different optical magnification methods. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 135-141.	1.3	24
115	Influence of genetic polymorphisms (IL-10/CXCL8/CXCR2/NF κ B) on the susceptibility of autoimmune rheumatic diseases. <i>Revista Brasileira De Reumatologia</i> , 2014, 54, 301-310.	0.7	0
116	Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 803-809.	0.9	123
117	Genetic polymorphisms of glutathione S-transferases and cytochrome P450 enzymes as susceptibility factors to systemic lupus erythematosus in southern Brazilian patients. <i>Molecular Biology Reports</i> , 2014, 41, 6167-6179.	2.3	9
118	Temporal development of muscle atrophy in murine model of arthritis is related to disease severity. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2013, 4, 231-238.	7.3	31
119	Assessing rheumatoid arthritis disease activity with ultrasound. <i>Clinical Rheumatology</i> , 2013, 32, 1249-1254.	2.2	24
120	Characteristics of NK cell activity in patients with systemic sclerosis. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 66-74.	0.7	3
121	Interleukin κ 10 Gene Promoter and <sc>NFKB</sc>1 Promoter Insertion/Deletion Polymorphisms in Systemic Sclerosis. <i>Scandinavian Journal of Immunology</i> , 2013, 77, 162-168.	2.7	26
122	Characterization of joint disease in mucopolysaccharidosis type I mice. <i>International Journal of Experimental Pathology</i> , 2013, 94, 305-311.	1.3	19
123	Muscle wasting in collagen-induced arthritis and disuse atrophy. <i>Experimental Biology and Medicine</i> , 2013, 238, 1421-1430.	2.4	31
124	CCR5 δ 32 in systemic lupus erythematosus: implications for disease susceptibility and outcome in a Brazilian population. <i>Lupus</i> , 2013, 22, 802-809.	1.6	21
125	Effect of Aqueous Extract of Giant Horsetail (<i>Equisetum giganteum</i> L.) in Antigen-Induced Arthritis. <i>Open Rheumatology Journal</i> , 2013, 7, 129-133.	0.2	13
126	Effect of Antioxidant Treatment on Fibrogenesis in Rats with Carbon Tetrachloride-Induced Cirrhosis. <i>ISRN Gastroenterology</i> , 2012, 2012, 1-7.	1.5	25

#	ARTICLE	IF	CITATIONS
127	Diminished Expression of Complement Regulatory Proteins on Peripheral Blood Cells from Systemic Lupus Erythematosus Patients. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	29
128	Vitamin D and polymorphisms of VDR gene in patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2012, 31, 1411-1421.	2.2	45
129	The role of <i>Bsm</i> and <i>Fok</i> vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D in Brazilian patients with systemic lupus erythematosus. <i>Lupus</i> , 2012, 21, 43-52.	1.6	77
130	The role of complement regulatory proteins in peripheral blood cells of patients with systemic lupus erythematosus: Review. <i>Cellular Immunology</i> , 2012, 277, 1-7.	3.0	17
131	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 2385-2395.	27.0	716
132	Combined effects of CXCL8 and CXCR2 gene polymorphisms on susceptibility to systemic sclerosis. <i>Cytokine</i> , 2012, 60, 473-477.	3.2	21
133	Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 186-191.	1.1	93
134	<i>TLR7/8/9</i> polymorphisms and their associations in systemic lupus erythematosus patients from Southern Brazil. <i>Lupus</i> , 2012, 21, 302-309.	1.6	61
135	O papel do gene e da molécula HLA-G na expressão clínica das doenças reumatólicas. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 82-91.	0.8	26
136	Mecanismos de perda muscular da sarcopenia. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 252-259.	0.8	31
137	Mannose-binding Lectin Gene Polymorphisms in Brazilian Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 6-9.	2.0	16
138	A combined enrichment/polymerase chain reaction based method for the routine screening of <i>Streptococcus agalactiae</i> in pregnant women. <i>Brazilian Journal of Microbiology</i> , 2012, 43, 253-260.	2.0	5
139	Growth Velocity and Interleukin 6 Concentrations: Applications to Juvenile Idiopathic Arthritis. , 2012, 1977-1987.		0
140	Mechanisms of muscle wasting in sarcopenia. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 252-9.	0.8	14
141	Nitric oxide regulates the repair of injured skeletal muscle. <i>Nitric Oxide - Biology and Chemistry</i> , 2011, 24, 43-49.	2.7	66
142	Association of the <i>HLA-DRB1</i> gene +3142C>G polymorphism with systemic lupus erythematosus. <i>Tissue Antigens</i> , 2011, 77, 540-545.	1.0	62
143	The role of nitric oxide during healing of trauma to the skeletal muscle. <i>Inflammation Research</i> , 2011, 60, 347-356.	4.0	30
144	Impact on the Quality of Life of an Educational Program for the Prevention of Work-Related Musculoskeletal Disorders: a randomized controlled trial. <i>BMC Public Health</i> , 2011, 11, 60.	2.9	32

#	ARTICLE	IF	CITATIONS
145	Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2956-2965.	6.7	30
146	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. <i>Journal of rheumatology Supplement, The</i> , 2011, 87, 54-58.	2.2	11
147	Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 15-24.	0.9	68
148	Doenas reumatolgicas autoimunes e sua associao com os genes killer immunoglobulin-like receptors. <i>Revista Brasileira De Reumatologia</i> , 2011, 51, 357-364.	0.8	9
149	The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 33, 202-206.	0.7	25
150	Clinical diagnostic performance of different methods for the detection of antibodies to extractable nuclear antigens in connective tissue diseases: a cohort study. <i>Clinical Laboratory</i> , 2011, 57, 625-9.	0.5	1
151	Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2010, 30, 369-373.	3.0	29
152	Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients. <i>Cellular Immunology</i> , 2010, 265, 127-132.	3.0	38
153	NT-proBNP levels in systemic sclerosis: Association with clinical and laboratory abnormalities. <i>Clinical Biochemistry</i> , 2010, 43, 745-749.	1.9	6
154	Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2010, 160, 325-330.	2.6	19
155	Sndrome metablica e artrite idioptica juvenil. <i>Revista Brasileira De Reumatologia</i> , 2010, 50, 190-197.	0.8	6
156	Mannose-binding lectin gene polymorphisms in Brazilian patients with systemic lupus erythematosus. <i>Lupus</i> , 2010, 19, 280-287.	1.6	22
157	Recomendaes nacionais baseadas em evidncias cientficas e opinies dos especialistas sobre o uso do metotrexato nas doenas reumticas, especialmente na artrite reumatoide: resultados da iniciativa 3E do Brasil. <i>Revista Brasileira De Reumatologia</i> , 2009, 49, 346-361.	0.8	10
158	O papel das protenas reguladoras do complemento CD55/CD59 em clulas de sangue perifrico de pacientes com lpus eritematoso sistmico. <i>Revista Brasileira De Reumatologia</i> , 2009, 49, 276-287.	0.8	8
159	Glu298Asp eNOS polymorphism is not associated with SLE. <i>Lupus</i> , 2009, 18, 448-451.	1.6	4
160	Acquired Factor XI Inhibitor in Systemic Lupus Erythematosus” Case Report and Literature Review. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 61-65.	3.4	31
161	Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 794-800.	6.7	162
162	Endothelial nitric oxide synthase T-786C polymorphism in rheumatoid arthritis: association with extraarticular manifestations. <i>Clinical Rheumatology</i> , 2009, 28, 201-205.	2.2	23

#	ARTICLE	IF	CITATIONS
163	Nitric oxide and repair of skeletal muscle injury. Nitric Oxide - Biology and Chemistry, 2009, 21, 157-163.	2.7	104
164	Association of the HLA-G 14Âbp polymorphism with systemic lupus erythematosus. Lupus, 2009, 18, 424-430.	1.6	83
165	Abdominal angiostrongyliasis: what does the rheumatologist must know about it?. International Journal of Rheumatic Diseases, 2009, 12, 267-271.	1.9	2
166	A pilot study of acupuncture as adjunctive treatment of rheumatoid arthritis. Clinical Rheumatology, 2008, 27, 627-635.	2.2	36
167	The role of mannose-binding lectin in systemic lupus erythematosus. Clinical Rheumatology, 2008, 27, 413-419.	2.2	71
168	Association Between the Aggrecan Gene and Rheumatoid Arthritis. Journal of Rheumatology, 2008, 35, 2325-2328.	2.0	3
169	Redox signalling and the inflammatory response in rheumatoid arthritis. Clinical and Experimental Immunology, 2008, 152, 415-422.	2.6	261
170	Association of the HLAâ€C 14â€bp insertion/deletion polymorphism with juvenile idiopathic arthritis and rheumatoid arthritis. Tissue Antigens, 2008, 71, 440-446.	1.0	64
171	Differential CCR5Î³32 allelic frequencies in juvenile idiopathic arthritis subtypes: evidence for different regulatory roles of CCR5 in rheumatological diseases. Scandinavian Journal of Rheumatology, 2008, 37, 13-17.	1.1	31
172	Effects of an antagonist of the bombesin/gastrin-releasing peptide receptor on complete Freund's adjuvant-induced arthritis in rats. Peptides, 2008, 29, 1726-1731.	2.4	20
173	Growth Velocity and Interleukin 6 Concentrations in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2008, 35, 2265-2271.	2.0	27
174	TCRBV20S1 and TCRBV3S1 gene segment polymorphisms in systemic sclerosis. Journal of Rheumatology, 2008, 35, 1058-63.	2.0	5
175	The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients. Scandinavian Journal of Rheumatology, 2007, 36, 359-364.	1.1	27
176	Subcutaneous inflammation (panniculitis) in tibio-tarsal joint of rats inoculated with complete Freundâ€™s adjuvant. Clinical and Experimental Medicine, 2007, 7, 184-187.	3.6	11
177	Oesophageal dysmotility in systemic sclerosis: comparison of HRCT and scintigraphy. British Journal of Radiology, 2006, 79, 719-724.	2.2	33
178	Raised serum S100B protein levels in neuropsychiatric lupus. Annals of the Rheumatic Diseases, 2006, 65, 829-831.	0.9	30
179	Effect of inflammatory activity and glucocorticoid [corrected] use on nutritional variables in patients with juvenile idiopathic arthritis. Journal of Rheumatology, 2006, 33, 601-8.	2.0	11
180	Neuropsychiatric systemic lupus erythematosus. Clinical Imaging, 2005, 29, 215-221.	1.5	50

#	ARTICLE	IF	CITATIONS
181	Nailfold capillaroscopic findings in primary Sjögren's syndrome: clinical and serological correlations. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 789-94.	0.8	19
182	Espondiloartropatias: espondilite anquilosante e artrite psoriásica. <i>Revista Brasileira De Reumatologia</i> , 2004, 44, 464-469.	0.8	0
183	Espondiloartropatias: outras artropatias. <i>Revista Brasileira De Reumatologia</i> , 2004, 44, 470-475.	0.8	0
184	Artrite reumatóide: diagnóstico e tratamento. <i>Revista Brasileira De Reumatologia</i> , 2004, 44, 435-442.	0.8	13
185	Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. <i>Journal of Rheumatology</i> , 2004, 31, 286-94.	2.0	63
186	Analysis of two T-cell receptor BV gene segment polymorphisms in caucasoid Brazilian patients with rheumatoid arthritis. <i>Immunology Letters</i> , 2003, 90, 77-80.	2.5	4
187	Serum S100B Levels in Patients with Lupus Erythematosus: Preliminary Observation. <i>Vaccine Journal</i> , 2002, 9, 164-166.	3.1	14
188	Lung clearance of 99mTc-DTPA in systemic lupus erythematosus. <i>Brazilian Journal of Medical and Biological Research</i> , 2002, 35, 663-668.	1.5	7
189	Ubiquitin-like polypeptide inhibits the IgE response of lipopolysaccharide-activated B cells. <i>International Immunology</i> , 1996, 8, 1659-1665.	4.0	14
190	Monoclonal nonspecific suppressor factor \hat{I}^2 inhibits interleukin-4 secretion by a type-2 helper T cell clone. <i>European Journal of Immunology</i> , 1995, 25, 2417-2419.	2.9	18
191	HLA class II genotyping by polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP) in systemic lupus erythematosus patients.. <i>Japanese Journal of Clinical Immunology</i> , 1995, 18, 289-295.	0.0	0
192	Molecular cloning and characterization of a cDNA encoding monoclonal nonspecific suppressor factor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 3463-3467.	7.1	59
193	The role of cyclic AMP in the lipopolysaccharide-induced suppression of thymidine kinase activity in macrophage. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1995, 1265, 201-208.	4.1	6
194	Antinuclear antibodies in healthy aging people: a prospective study. <i>Mechanisms of Ageing and Development</i> , 1995, 78, 145-154.	4.6	68
195	Human Nonspecific Suppressor Factor (hNSF): Cell Source and Effects on T and B Lymphocytes. <i>Immunobiology</i> , 1995, 192, 262-271.	1.9	6
196	Monoclonal non-specific suppressor factor (MNSF) inhibits the IL4 secretion by bone marrow-derived mast cell (BMMC). <i>FEBS Letters</i> , 1994, 339, 239-242.	2.8	16
197	Isolation and characterization of a human nonspecific suppressor factor from ascitic fluid of systemic lupus erythematosus. Evidence for a human counterpart of the monoclonal nonspecific suppressor factor and relationship to the T cell receptor alpha-chain. <i>Journal of Immunology</i> , 1994, 152, 2624-32.	0.8	13
198	HOSPITALIZATION AND MORTALITY RATE RELATED TO COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES ON CHRONIC USE OF HYDROXYCHLOROQUINE: 16-WEEK PRELIMINARY DATA FROM THE MARIO PINOTTI STUDY. , 0, , .		0

#	ARTICLE	IF	CITATIONS
199	CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUANTILES. , 0, , .		0
200	CHRONIC USE OF HYDROXYCHLOROQUINE DID NOT PROTECT AGAINST COVID-19 IN A LARGE COHORT OF PATIENTS WITH RHEUMATIC DISEASES IN BRAZIL. , 0, , .		0
201	Lupus-Like syndrome induced by uterine sarcoma: a case report. , 0, , .		0
202	TREATMENT WITH VITAMIN D PREVENTS MUSCLE ATROPHY IN PRISTANE-INDUCED LUPUS MODEL. , 0, , .		0
203	SUBJECTIVE FATIGUE AND SKELETAL MUSCLE ARE ASSOCIATED WITH MUSCLE METABOLIC PROFILE IN RHEUMATOID ARTHRITIS. , 0, , .		0
204	THE ROLE OF GASTRIN-RELEASING PEPTIDE IN MYOFIBROBLAST ACTIVATION OF COLON FIBROBLASTS. , 0, , .		0
205	FASCIOLA HEPATICA EXTRACT ALTERS VIABILITY, ADHESION, MIGRATION AND INVASION PROPERTIES OF SYNOVIAL FIBROBLASTS FROM PATIENTS WITH RHEUMATOID ARTHRITIS.. , 0, , .		0
206	DEVELOPMENT OF A NOVEL METHOD TO ASSESS SKELETAL MUSCLE ATROPHY IN COLLAGEN INDUCED ARTHRITIS (CIA) MODEL. , 0, , .		0
207	DIFFERENT RESPONSES OF FIBROBLAST-LIKE SYNOVIOCYTES FROM PATIENTS WITH RHEUMATOID ARTHRITIS AND FROM MICE WITH COLLAGEN-INDUCED ARTHRITIS TO INFLAMMATORY STIMULI. , 0, , .		0
208	LUPUS MYOCARDITIS AND SEVERE HEART FAILURE. , 0, , .		0
209	DISEASE ACTIVITY STATUS AND AND PHYSICAL FUNCTIONING IS ASSOCIATED WITH LOW MUSCLE MASS RELATIVE TO FAT MASS IN RHEUMATOID ARTHRITIS. , 0, , .		0
210	EVALUATION OF MYOKINES SERUM LEVELS, MUSCLE MASS AND RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 0, , .		0
211	Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area. Clinical and Biomedical Research, 0, , .	0.1	0
212	Development of new adjusted equations to estimate the skeletal muscle mass stratified by nutritional status for patients with rheumatoid arthritis: a methodological study. Revista Brasileira De Cineantropometria E Desempenho Humano, 0, 23, .	0.5	1
213	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 0, , .	0.8	1